Conference Coverage

Be mindful of psoriasis/cutaneous T-cell lymphoma link


 

EXPERT OPINION FROM SDEF HAWAII DERMATOLOGY SEMINAR

Dr. Guy F. Webster

"Is the use of an anti-TNF agent going to increase that risk? The answer is that in all of the more than 2 million patients who’ve been treated with TNF inhibitors, there does not appear to be a statistical increase above the baseline risk," said Dr. Menter of Baylor University Medical Center, Dallas, and chair of the American Academy of Dermatology psoriasis guidelines committee.

SDEF and this news organization are owned by the same parent company. Dr. Menter, Dr. Gelfand, Dr. Webster, and Dr. Leonardi have received research funds and/or served as consultants to numerous pharmaceutical companies.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

ACE Inhibitors Up Mortality Risk When Given Prior to Scleroderma Renal Crisis
MDedge Family Medicine
Ustekinumab's Cardiovascular Event Rates Stable at 5 Years
MDedge Family Medicine
Subcutaneous Nodules Linked to Cardiovascular Disease Risk in RA
MDedge Family Medicine
Psoriasis Patients Have Low Rates of Common Cancers
MDedge Family Medicine
Stroke caution on thalidomide for cutaneous LE
MDedge Family Medicine
PDE-5 inhibitors decrease secondary Raynaud's attacks
MDedge Family Medicine
Pregnancies after vasculitis diagnosis are at risk
MDedge Family Medicine
Systemic steroid prescriptions for psoriasis persist
MDedge Family Medicine
All glucocorticoids linked to increased risk of VTE
MDedge Family Medicine
Exceeding 10 mg/day prednisone increased CV events in lupus
MDedge Family Medicine